Cogent Biosciences(NASDAQ) COGT

Cogent makes precision medicines for rare genetic diseases. These drugs target mutations that cause cells to grow unchecked. The company focuses on patients with limited treatment options.

What Cogent is Developing

• Bezuclastinib: A protein blocker designed to treat rare blood disorders and stomach cancers.
• ErbB2 Inhibitor: A therapy candidate currently being tested for lung cancer and other solid tumors.
• PI3Kα Inhibitor: A specialized medicine designed to treat breast cancer while avoiding healthy cells.
• Discovery Programs: Early-stage projects focused on genetic mutations in colorectal and lung cancers.

Strategic Growth and Partnerships

• Secured global development rights for bezuclastinib through a license with Plexxikon.
• Submitted a New Drug Application (NDA) to the FDA in December 2025 for its lead candidate.
• Launched an expanded access program in 2025 to provide medicines to patients before official approval.
• Started Phase 1 clinical trials for new cancer drug candidates in late 2025 and early 2026.

Specialized Research and Innovation

Cogent builds its own drugs using a specialized research team in Boulder, Colorado. This team creates medicines that hit specific genetic targets without harming healthy tissue.

Tracking the Recent Numbers

• Operating loss was $103.6 million in Q1 2026, worsened 38.3% year-over-year.
• Net loss hit $97.4 million in Q1 2026, deepened 35.2% from $72 million in Q1 2025.
• Research and development spending reached $75.4 million in Q1 2026.
• Cash and marketable securities totaled $866.4 million as of March 31, 2026.

Bottom Line

Cogent is evolving from a research-focused group into a commercial drug company. Its long-term progress depends on the regulatory approval and launch of its lead precision therapy.